title: [Current multidisciplinary treatment of metastatic prostatic cancer].
abstract: Prostate cancer is one of the commonest causes of cancer-related death in the western world. The morbi-mortality associated is usually a direct consequence of metastatic spread to bone, in up to 50% of patients at first presentation. The aim of treatment of metastatic patients is to alleviate and to prevent the distressing symptoms. The approach include hormone-therapy, radiotherapy, radio-nuclides, surgery, chemotherapy, bisphosphonates and new drugs (agents that inhibit angiogenesis, immunotherapy and therapies that affect the differentiation). Decisions about therapy must also take into consideration the androgen-dependent or independent, so hormone-therapy is the first step of the treatment; the number and location of bone metastases; the severity of symptoms; the available of therapies; the status performance of patient; the prognosis and the cost-effect relationship. Some treatments have established indications whereas others are still in process of study in order to determinate their efficacy, their model of treatment and their indications. This article revises and updates these treatments.
authors.affiliation: Servicio de Oncología Radioterápica, Hospital Clínico Universitario de Valencia.
authors.forename: M
authors.initials: M
authors.lastname: Rodríguez Cordón
authors.forename: E
authors.initials: E
authors.lastname: Ferrer Albiach
authors.forename: C
authors.initials: C
authors.lastname: Ferrer Albiach
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000556:secondary* / Q000628:therapy*; D003131:Combined Modality Therapy; D006728:Hormones / Q000627:therapeutic use; D006801:Humans; D008297:Male; D011471:Prostatic Neoplasms / Q000473:pathology*; D019275:Radiopharmaceuticals / Q000627:therapeutic use
chemical_list: D000970:Antineoplastic Agents; D006728:Hormones; D019275:Radiopharmaceuticals